Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €94.50 EUR
Change Today -0.60 / -0.63%
Volume 0.0
ICY On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 4:22 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

incyte corp (ICY) Snapshot

Open
€94.60
Previous Close
€95.10
Day High
€94.88
Day Low
€94.38
52 Week High
07/15/15 - €110.56
52 Week Low
08/8/14 - €33.52
Market Cap
16.9B
Average Volume 10 Days
705.2
EPS TTM
--
Shares Outstanding
179.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INCYTE CORP (ICY)

incyte corp (ICY) Related Businessweek News

No Related Businessweek News Found

incyte corp (ICY) Details

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, which is in Phase III clinical trial for pancreatic cancer; and in Phase II trial for the treatment of breast cancer, non-small cell lung cancer, and colorectal cancer, as well as INCB39110 that is in Phase I/II trial for malignancies; and in Phase II trial for non-small cell lung cancer. The company’s product pipeline also comprises INCB52793, which is in Phase I/II clinical trial for the treatment of B-lymphoid malignancies; INCB50465 that is in Phase I/II clinical trial for hematology/oncology; and INCB39110+INCB40093, which is in Phase I/II trial for B-lymphoid malignancies. In addition, it is developing epacadostat that is in Phase II clinical trial for metastatic melanoma, as well as in Phase I/II trial for non-small cell lung cancer and various tumor types; and capmatinib, which is in Phase I/II clinical trial for the treatment of solid tumors, as well as in Phase II trial for hepatocellular carcinoma and non-small cell lung cancer. Further, the company is developing INCB54828 that is in Phase I/II clinical trial for the treatment of solid tumors; INCB54329, which is in Phase I/II clinical trial for the treatment of hematology/oncology; and baricitinib that is in Phase III trial for rheumatoid arthritis, as well as in Phase IIb clinical trial for psoriasis, and Phase II trial for diabetic nephropathy. It has a collaboration and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

588 Employees
Last Reported Date: 02/17/15
Founded in 1991

incyte corp (ICY) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $2.9M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $113.8K
Chief Drug Development Officer and Executive ...
Total Annual Compensation: $403.0K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $365.6K
Executive Vice President of Human Resources
Total Annual Compensation: $354.0K
Compensation as of Fiscal Year 2014.

incyte corp (ICY) Key Developments

Incyte Corporation and Vanderbilt-Ingram Cancer Center Establish Multi-Year Oncology Research Alliance

Incyte Corporation announced that it has entered into a multi-year research support and collaboration agreement with Vanderbilt-Ingram Cancer Center (VICC) at Vanderbilt University Medical Center (VUMC), whereby Incyte will provide funding for certain aspects of Vanderbilt’s cancer research activities. This alliance is designed to develop an improved understanding of basic cancer biology and the mechanisms of action of certain Incyte-proprietary compounds, as well as identify and develop novel approaches to patient selection which may enable new therapeutic opportunities in oncology.

ImmunoVaccine Inc. Collaborates with Incyte Corporation to Evaluate Novel Immunotherapy Combination for Patients with Platinum sensitive Ovarian Cancer

Immunovaccine Inc. announced that it has entered into a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the combination of Immunovaccine's novel T cell activating immunotherapy, DPX-Survivac, with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). Immunovaccine and Incyte will co-fund and conduct a multicenter, open-label Phase 1B study to evaluate the safety, tolerability and efficacy of the novel combination in platinum-sensitive ovarian cancer patients who are at high risk of recurrence. The investigational new drug (IND) application for the study, which will test the triple combination of DPX-Survivac, epacadostat and low dose oral cyclophosphamide, is expected to be filed in 2015 in the U.S. and Canada and the study is expected to enroll approximately 20 patients. Results from this study may lead to an expansion of the clinical collaboration to investigate other cancers. DPX-Survivac and epacadostat both target pathways that have been linked to cancer progression, namely survivin and IDO1. High levels of survivin and IDO1 are found in a broad range of cancers, including ovarian cancer, and individually have been shown to correlate with poor patient outcomes. DPX-Survivac is designed to activate T cells of the immune system to recognize survivin-expressing cancer cells. Epacadostat, on the other hand, is designed to inhibit IDO1-mediated immune suppression in the tumor microenvironment. It is therefore hypothesized that co-administration of these immunotherapies may lead to enhanced anti-tumor effects by both activating the immune system to recognize the cancer and simultaneously weakening its defenses.

Incyte Corporation Presents at Piper Jaffray Heartland Summit, Jun-23-2015

Incyte Corporation Presents at Piper Jaffray Heartland Summit, Jun-23-2015 . Venue: Minneapolis, Minnesota, United States. Speakers: Herve Hoppenot, Chief Executive Officer, President, Director and Member of Non-Management Stock Option Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICY:GR €94.50 EUR -0.60

ICY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $70.33 USD +0.31
ARIAD Pharmaceuticals Inc $8.06 USD -0.10
BioMarin Pharmaceutical Inc $147.17 USD +0.90
Jazz Pharmaceuticals PLC $192.77 USD +0.53
Vertex Pharmaceuticals Inc $136.99 USD +1.99
View Industry Companies
 

Industry Analysis

ICY

Industry Average

Valuation ICY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 30.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 29.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INCYTE CORP, please visit www.incyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.